Cryptosporidium parvum is a highly prevalent zoonotic and anthroponotic protozoan parasite that causes a diarrheal syndrome in children and neonatal livestock, culminating in growth retardation and mortalities. Disclosed herein are inhibitors against the enzymatic activity of recombinant CpLDH protein that were identified. The inhibitors were tested for anti-Cryptosporidium effect using in vitro infection assays of HCT-8 cells monolayers. Compounds NSC158011 and NSC10447 were identified to inhibit the proliferation of intracellular C. parvum in vitro, with IC50 values of 14.88 and 72.65 μM, respectively. At doses tolerable in mice, both NSC158011 and NSC10447 significantly reduced the shedding of C. parvum oocysts in infected immunocompromised mice's feces and prevented intestinal villous atrophy as well as mucosal erosion due to C. parvum. These findings have unveiled anti-Cryptosporidium drug candidates that can be explored further for the development of therapeutic agents against C. parvum infections.

Cryptosporidium parvum is a highly prevalent zoonotic and anthroponotic protozoan parasite that causes a diarrheal syndrome in children and neonatal livestock, culminating in growth retardation and mortalities. Disclosed herein are inhibitors against the enzymatic activity of recombinant CpLDH protein that were identified. The inhibitors were tested for anti-Cryptosporidium effect using in vitro infection assays of HCT-8 cells monolayers. Compounds NSC158011 and NSC10447 were identified to inhibit the proliferation of intracellular C. parvum in vitro, with IC50 values of 14.88 and 72.65 μM, respectively. At doses tolerable in mice, both NSC158011 and NSC10447 significantly reduced the shedding of C. parvum oocysts in infected immunocompromised mice's feces and prevented intestinal villous atrophy as well as mucosal erosion due to C. parvum. These findings have unveiled anti-Cryptosporidium drug candidates that can be explored further for the development of therapeutic agents against C. parvum infections.

The present invention is a method of making 1,4,5,8-tetrakis(R-phenylamino)anthracene-9,10-dione (where R is H or a hydrocarbyl group) comprising the step of contacting 1,4,5,8-tetrachloroanthraquinone with a mixture of R-anilines comprising at least two different R groups, under conditions to produce 1,4,5,8-tetrakis(R-phenylamino)anthracene-9,10-dione. The present disclosure also provides a reaction mixture of 1,4,5,8-tetrakis(R-phenylamino)anthracene-9,10-dione characterized by having the R groups on at least 75% of the 1,4,5,8-tetrakis(R-amino)anthracene-9,10-dione molecules in the mixture be comprised of 2 or more different R groups. The present disclosure also provides a method of improving the solubility of 1,4,5,8-tetrakis(R-phenylamino)anthracene-9,10-dione in aromatic hydrocarbons distilled from crude oil, comprising selecting a mixture of 1,4,5,8-tetrakis(R-phenylamino)anthracene-9,10-diones which are characterized by having at least 75% of the 1,4,5,8-tetrakis(R-phenylamino)anthracene-9,10-dione molecules in the mixture comprise two or more different R groups. The compounds of the present invention exhibit a suitable UV visible absorbance profile making them suitable for use as a fuel marker.

The present invention is a method of making 1,4,5,8-tetrakis(R-phenylamino)anthracene-9,10-dione (where R is H or a hydrocarbyl group) comprising the step of contacting 1,4,5,8-tetrachloroanthraquinone with a mixture of R-anilines comprising at least two different R groups, under conditions to produce 1,4,5,8-tetrakis(R-phenylamino)anthracene-9,10-dione. The present disclosure also provides a reaction mixture of 1,4,5,8-tetrakis(R-phenylamino)anthracene-9,10-dione characterized by having the R groups on at least 75% of the 1,4,5,8-tetrakis(R-amino)anthracene-9,10-dione molecules in the mixture be comprised of 2 or more different R groups. The present disclosure also provides a method of improving the solubility of 1,4,5,8-tetrakis(R-phenylamino)anthracene-9,10-dione in aromatic hydrocarbons distilled from crude oil, comprising selecting a mixture of 1,4,5,8-tetrakis(R-phenylamino)anthracene-9,10-diones which are characterized by having at least 75% of the 1,4,5,8-tetrakis(R-phenylamino)anthracene-9,10-dione molecules in the mixture comprise two or more different R groups. The compounds of the present invention exhibit a suitable UV visible absorbance profile making them suitable for use as a fuel marker.

The present invention provides di-substituted acetalanthraquinone-based compounds of the Formulae (l)-(IV) that are useful for cellular staining and for light-based detection of biological material, e.g. fluorescence-based detection of biological material. These compounds may be used in hydrolysed or non-hydrolysed form. Also provided is a fluorescent complex that comprises a nucleic acid and an acetalanthraquinone-based compound of the invention; and a method of staining a biological sample comprising cells or other biological material containing nucleic acid, which method comprises contacting the biological sample with an acetalanthraquinone-based compound of the invention. In the Formulae (l)-(IV), A and B are each independently of formula —R.sup.aCH.sub.2CH(OR.sup.b).sub.2; or one of A and B is of formula —R.sup.aCH.sub.2CH(OR.sup.b).sub.2 and the other one is of formula: —NR.sup.b.sub.2. ##STR00001##

The present invention provides di-substituted acetalanthraquinone-based compounds of the Formulae (l)-(IV) that are useful for cellular staining and for light-based detection of biological material, e.g. fluorescence-based detection of biological material. These compounds may be used in hydrolysed or non-hydrolysed form. Also provided is a fluorescent complex that comprises a nucleic acid and an acetalanthraquinone-based compound of the invention; and a method of staining a biological sample comprising cells or other biological material containing nucleic acid, which method comprises contacting the biological sample with an acetalanthraquinone-based compound of the invention. In the Formulae (l)-(IV), A and B are each independently of formula —R.sup.aCH.sub.2CH(OR.sup.b).sub.2; or one of A and B is of formula —R.sup.aCH.sub.2CH(OR.sup.b).sub.2 and the other one is of formula: —NR.sup.b.sub.2. ##STR00001##

The present invention provides di-substituted acetalanthraquinone-based compounds of the Formulae (l)-(IV) that are useful for cellular staining and for light-based detection of biological material, e.g. fluorescence-based detection of biological material. These compounds may be used in hydrolysed or non-hydrolysed form. Also provided is a fluorescent complex that comprises a nucleic acid and an acetalanthraquinone-based compound of the invention; and a method of staining a biological sample comprising cells or other biological material containing nucleic acid, which method comprises contacting the biological sample with an acetalanthraquinone-based compound of the invention. In the Formulae (l)-(IV), A and B are each independently of formula R.sup.aCH.sub.2CH(OR.sup.b).sub.2; or one of A and B is of formula R.sup.aCH.sub.2CH(OR.sup.b).sub.2 and the other one is of formula: NR.sup.b.sub.2.

##STR00001##

Cryptosporidium parvum is a highly prevalent zoonotic and anthroponotic protozoan parasite that causes a diarrheal syndrome in children and neonatal livestock, culminating in growth retardation and mortalities. Disclosed herein are inhibitors against the enzymatic activity of recombinant CpLDH protein that were identified. The inhibitors were tested for anti-Cryptosporidium effect using in vitro infection assays of HCT-8 cells monolayers. Compounds NSC158011 and NSC10447 were identified to inhibit the proliferation of intracellular C. parvum in vitro, with IC50 values of 14.88 and 72.65 M, respectively. At doses tolerable in mice, both NSC158011 and NSC10447 significantly reduced the shedding of C. parvum oocysts in infected immunocompromised mice's feces and prevented intestinal villous atrophy as well as mucosal erosion due to C. parvum. These findings have unveiled anti-Cryptosporidium drug candidates that can be explored further for the development of therapeutic agents against C. parvum infections.

Cryptosporidium parvum is a highly prevalent zoonotic and anthroponotic protozoan parasite that causes a diarrheal syndrome in children and neonatal livestock, culminating in growth retardation and mortalities. Disclosed herein are inhibitors against the enzymatic activity of recombinant CpLDH protein that were identified. The inhibitors were tested for anti-Cryptosporidium effect using in vitro infection assays of HCT-8 cells monolayers. Compounds NSC158011 and NSC10447 were identified to inhibit the proliferation of intracellular C. parvum in vitro, with IC50 values of 14.88 and 72.65 M, respectively. At doses tolerable in mice, both NSC158011 and NSC10447 significantly reduced the shedding of C. parvum oocysts in infected immunocompromised mice's feces and prevented intestinal villous atrophy as well as mucosal erosion due to C. parvum. These findings have unveiled anti-Cryptosporidium drug candidates that can be explored further for the development of therapeutic agents against C. parvum infections.

Cryptosporidium parvum is a highly prevalent zoonotic and anthroponotic protozoan parasite that causes a diarrheal syndrome in children and neonatal livestock, culminating in growth retardation and mortalities. Disclosed herein are inhibitors against the enzymatic activity of recombinant CpLDH protein that were identified. The inhibitors were tested for anti-Cryptosporidium effect using in vitro infection assays of HCT-8 cells monolayers. Compounds NSC158011 and NSC10447 were identified to inhibit the proliferation of intracellular C. parvum in vitro, with IC.sub.50 values of 14.88 and 72.65 M, respectively. At doses tolerable in mice, both NSC158011 and NSC10447 significantly reduced the shedding of C. parvum oocysts in infected immunocompromised mice's feces and prevented intestinal villous atrophy as well as mucosal erosion due to C. parvum. These findings have unveiled anti-Cryptosporidium drug candidates that can be explored further for the development of therapeutic agents against C. parvum infections.